慢性淋巴细胞白血病患者的管理策略 隐藏复杂的型
Andrea Serafin1, Valeria Ruocco1, Alessandro Cellini1
1Hematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.
British journal of haematology
|January 6, 2025
概括
慢性淋巴细胞白血病 (CLL) 与复杂的型 (CK) 表示预后不佳. 本综述涵盖了这个具有挑战性的CLL子集的分子景观,诊断和治疗方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是一种异质的淋巴细胞恶性瘤.
- 复杂型 (CK) 的CLL患者的一个子组表现出不良的预后和有限的治疗选择.
研究的目的:
- 审查目前对CLL与CK的理解.
- 讨论这个患者群体的分子特征,诊断,治疗和新兴疗法.
- 概述个性化的管理策略,以改善结果.
主要方法:
- 现有关于CK的CLL研究的文献综述.
- 分析分子景观,诊断工具和治疗方式.
- 综合有关新兴疗法和个性化管理的信息.
主要成果:
- 结合CK的CLL与侵袭性疾病生物学有关.
- 目前,与CK结合的CLL的治疗选择往往有限.
- 新兴疗法对这一子集有前途.
结论:
- 了解CLL与CK的分子基础至关重要.
- 个性化治疗策略对于改善CK的CLL患者的治疗结果至关重要.
- 对于这一高风险群体,需要对新型疗法进行进一步的研究.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Karyotyping
57.3K
Overview
57.3K


